Ultragenyx reports Q2 EPS ($1.17), consensus ($1.32)

Reports Q2 revenue $166.5M, consensus $161.37M. “In the first half of the year, we delivered 20% revenue growth from our commercial therapies versus the prior year. We are continuing along our path to profitability in 2027, as we drive our top line growth and maintain our fiscal discipline,” said Emil D. Kakkis, chief executive officer and president of Ultragenyx (RARE). “We are excited for the potential of UX143 in osteogenesis imperfecta to reduce fractures and meaningfully improve patients’ bone health and for GTX-102 in Angelman syndrome to transform the lives of patients and their families affected by this neurodevelopment disease.”